Kornimate/medical-research-clean huggingface dataset:
investigation of effectiveness of telerehabilitation for zone 2 flexor tendon injuries of the hand

Conditions: Zone 2 Flexor Tendon Injuries of the Hand

Summary: the treatment process following zone 2 flexor tendon injuries, which are particularly controversial for hand surgery, is challenging. there are various rehabilitation methods for zone 2 flexor tendon injuries, one of which is the modified duran protocol. disruptions in the physiotherapy process lead to joint contractures, tendon adhesions, and limitations in daily life activities for patients. due to global issues such as socioeconomic factors, physical barriers, distance, and pandemics, patients who cannot actively participate in physiotherapy miss out on the rehabilitation process. the aim of the present study is to investigate the effectiveness of the modified duran protocol applied through telerehabilitation following zone 2 flexor tendon repair. between april and october 2024, a total of 42 adults aged 18-55 who underwent zone 2 flexor tendon repair at istanbul university istanbul faculty of medicine will be recruited, with 21 participants in face-to-face clinic group and 21 in telerehabilitation group. rehabilitation process will be followed for 12 weeks. the telerehabilitation group will receive exercise training on the third day. after the first training session, patients will be discharged and called to the clinic once a week for dressing changes, monitoring, exercises and if necessary, revision of the protective splint. patients will be contacted three times a week to implement the planned program using telerehabilitation. the face-to-face rehabilitation group will receive face-to-face clinic rehabilitation three times a week under the supervision of a physiotherapist for the first 12 weeks. patients will be evaluated at the end of the 5th, 6th, and 12th weeks. data collection tools will include a 'sociodemographic form', 'disabilities of the arm, shoulder, and hand (dash) questionnaire', 'visual analog scale (vas)', 'jamar hand dynamometer', and 'goniometer (joint range of motion)'. spss (statistical package for the social sciences) statistics will be used for the statistical analysis of all data, with a significance level of p \<0.05 considered significant in all assessments, and accepted as two-tailed.


Eligibility criteria:
inclusion criteria: * individuals with isolated zone 2 flexor digitorum profundus (fdp) and flexor digitorum superficialis (fds) injuries, * repair performed within the first 72 hours post-injury, * individuals aged between 18 and 55 years, * patients willing to participate in the study, * ability to attend sessions regularly. exclusion criteria: * fingers with concomitant fractures, digital nerve injuries, vascular injuries, or significant skin loss accompanying flexor tendon injuries, * bilateral flexor tendon injuries, * patients with replantation or revascularization, * flexor pollicis longus tendon injuries of the thumb due to differences in protocols applied and measurement of final outcomes, * patients unable to understand and perform postoperative exercises
phase 2 study of spi-2012 or pegfilgrastim for the management of neutropenia in participants with breast cancer

Conditions: Neutropenia

Summary: the purpose of this study is to assess the effect of test doses of spi-2012 on the duration of severe neutropenia (dsn) during cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.

this is an open label, multicenter, dose ranging study, sequentially enrolled by study dose, with a non-inferiority design to compare the effectiveness of spi-2012 relative to a fixed dose of pegfilgrastim as a concurrent active control to each dose of spi-2012 in participants with breast cancer. this study included four arms comprising three dose levels of spi-2012 (arm 1: 45 µg/kg, arm 2: 135 µg/kg, arm 3: 270 µg/kg) versus pegfilgrastim (arm 4: 6 mg). the start of study is defined as the initiation of treatment with spi-2012 or pegfilgrastim. the duration of treatment consists of a maximum of 4 cycles (21 days per cycle) beginning on day 1 with chemotherapy administration and continue through day 21, plus a 30-day follow-up period, unless any of the discontinuation criteria applies. the target population are participants with breast cancer who are candidates for neoadjuvant or adjuvant treatment with docetaxel + cyclophosphamide (tc) chemotherapy. all participants who receive at least 1 dose of either spi-2012 or pegfilgrastim were followed for safety through 30 days after their last dose of study treatment or until all treatment-related adverse events (aes) have resolved or returned to baseline/grade 1, whichever is longer, or until it is determined that the outcome will not change with further follow-up.

Eligibility criteria:
inclusion criteria: * histologically confirmed breast cancer and candidate for adjuvant or neoadjuvant chemotherapy * candidate for docetaxel and cyclophosphamide chemotherapy * female or male at least 18 years of age * eastern cooperative oncology group (ecog) ≤ 2 * absolute neutrophil count (anc) ≥ 1.5×109/l * platelet count ≥ 100 x 10\^9/l * creatinine ≤ 1.5 x upper limit of normal (uln) * total bilirubin ≤1.5 mg/dl(≤ 25.65 μmol/l). * aspartate aminotransferase per serum glutamic-oxaloacetic transaminase (ast/sgot) and/or alanine aminotransferase per serum glutamic-pyruvic transaminase (alt/sgpt) ≤ 2.5 x uln * hemoglobin \> 9 g/dl * alkaline phosphatase ≤ 1.5 x uln exclusion criteria: * known sensitivity to e. coli-derived products or known sensitivity to any of the products to be administered * known human immunodeficiency virus (hiv) infection * hepatitis b virus (hbv) or hepatitis c virus (hcv) diagnosis with detectable viral load or immunological evidence of chronic active disease * active infection or any serious underlying medical condition that would impair ability to receive protocol treatment * prior bone marrow or stem cell transplant * prolonged exposure to glucocorticosteroids and immunosuppressive agents
risk perception in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with rms (rrms and spms). patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (hets) and those who were prescribed with non-high efficacy treatments (non-hets). het include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-hets include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.

the study cohort consisted of rms patients identified in the adelphi real world ms dsp, which was current up until the q2/2021. the study was using waves vi-ix of the adelphi dsp dataset. study period: q1 2017 - q1 \& q2 2021 (waves vi-ix of adelphi dsp dataset). identification period: q1 2017 - q1 \& q2 2021 (waves vi-ix of adelphi dsp dataset). index date: defined as the dates when the surveys were carried out (q1 2017 - q1 \& q2 2021).

Eligibility criteria:
inclusion criteria: * patients included in the database with a diagnosis of rrms and spms. * patients with current treatment at the index date. * patients with previous treatment at the index date. * patients to whom the physician decided to switch the treatment from the previous treatment to current treatment at the index date. * patients (males \& females) with 18 years or older at index date. exclusion criteria: * patients included in the database with the diagnosis of primary progressive ms (ppms). * patients with other major neurological or psychiatric condition, which could potentially hinder the analysis.

Keywords: multiple sclerosis (ms), disease-modifying therapies (dmts), high efficacy treatments (hets), nonhigh efficacy treatments (non-hets)
effects of a myofascial technique on biomechanical properties of the lumbar myofascia of chronic low back pain adults

Conditions: Chronic Low Back Pain

Summary: non-specific low back pain is a worldwide health issue that remains poorly understood. some authors have shown that the thoracolumbar fascia of low back pain adults presents changes in biomechanical properties. as it is richly endowed with pain receptors, the thoracolumbar fascia could therefore be a key contributor to this chronic pain condition. myofascial techniques (mfts) are commonly used in manual therapy by practitioners of various backgrounds to address fascia biomechanical properties, but there is a paucity of objective evidence on their effects on tissue state. musculoskeletal ultrasonography, sonoelastography and myometry are emerging imaging techniques that can quantify the biomechanical properties of fascia and underlying muscle. these innovative techniques could in turn contribute to a better understanding of mfts effects on fascial properties. the main objective of this study is to evaluate the immediate effect of a standardized mft on the elastography features of the lumbar paraspinal muscle and fascia (i.e. myofascial unit). the secondary objectives are to evaluate the immediate effects of a mft on: i) ultrasonography features of the myofascial unit; ii) myometry features of the myofascial unit; ii) pain intensity.


Eligibility criteria:
inclusion criteria: * adults over 18 years of age, * lumbar pain and/or referred pain above or below the gluteal fold , with intensity \> 3/10, persisting for \> 6 months and presenting during the day \> 50% of the time. exclusion criteria: * history of serious spinal or lower extremity injury or surgery in the last year * identifiable back pain or known pathology * known rheumatological condition * oral or injectable corticosteroids in the lumbar spine within the last 3 months * psychiatric disorder * pregnancy * manual treatment of the lumbo-sacral region 1 month prior to the experimentation and during the week of the study

Keywords: low back pain fascia properties thoracolumbar fascia myofascial release manual therapy osteopathy ultrasound imaging sonoelastography
qigong for pre-frail and frail older cancer survivors

Conditions: Cancer; Frailty

Summary: to-date, there is no evidence on qigong's effects for improving well-being of pre-frail and frail older cancer survivors. our aim is to conduct a pilot study for testing out the feasibility and acceptability of a qigong intervention to the elderly cancer survivors.

frailty is an emerging concept in geriatric research and practice. it is defined as a state of increased vulnerability to adverse outcomes including death. a cohort study has found that respondents with cancer were significantly more frail compared to those without cancer. a plausible explanation is both cancer itself and the therapies used to treat it add additional stressors that challenge a patient's physiologic reserve. a systematic review has revealed a high prevalence of frailty and pre-frailty in older cancer patients, with the median estimates of 42% and 43%, respectively. cancer treatment can hasten survivors' aging process and increase their risk of developing frailty, thus placing cancer survivors at heightened risk of such poor health outcomes as falls, fractures, and disability. this calls for effective interventions that would improve frailty in older cancer survivors. qigong, a type of mind-body intervention, is particularly suitable for older adults, as it is implemented without aerobic and musculoskeletal strain. this equipment-free form of exercise is ideal for settings with limited resources, as well as for the frail elderly, because it can be performed at home at any time, reducing such barriers as weather, transportation, and cost. meta-analysis suggests that baduanjin is beneficial in the general population in terms of improved quality of life, balance, handgrip strength, and trunk flexibility. to our knowledge, there is no evidence on qigong's effects for improving well-being of pre-frail and frail older cancer survivors. our aim is therefore to conduct a pilot study for testing out the feasibility and acceptability of a qigong intervention to the elderly cancer survivors.

Eligibility criteria:
inclusion criteria: 1. aged ≥65 2. diagnosed with stage i-iii non-metastatic cancer 3. completed primary treatment with curative intent (surgery, chemotherapy, and/or radiation therapy) 6 months to 5 years prior to baseline assessments with no recurrence or occurrence of additional cancers 4. classified as pre-frail or frail based on fried frailty criteria 5. can communicate in cantonese or putonghua 6. written informed consent exclusion criteria: 1. regular qigong training or other mind body intervention (once or more per week) within the previous 6 months 2. medical conditions affecting mobility, predisposing to falls, or precluding qigong practice (e.g., neurological disease, musculoskeletal disorder, recent myocardial infarction, breathing difficulties requiring oxygen)

Keywords: frailty cancer survivors qigong feasibility
long term experience with abatacept in routine clinical practice

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to estimate the retention rate of abatacept over 24 months in routine clinical practice in every participating country depending on the treatment line.

time perspective: other: collection of the baseline data collected at abatacept iv initiation, prospectively or retrospectively within maximum 3 months following the first administration. other assessments are collected during the follow up period (maximum of 2 years by patient) biospecimen retention: none retained excepted for a local sub study (in spain) where sample with dna was retained

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * male or female subjects of more than 18 years old * patients with a diagnosis of established moderate to severe active ra (as per the american college of rheumatology revised criteria, 1987), who at their physician's discretion are treated with abatacept according to the smpc in europe and the product monograph in canada (initiating or already on treatment for maximum 3 months) and for whom baseline characteristics are available exclusion criteria: * patients who are currently included in any interventional clinical trial in ra
effects of the drug ketoconazole on how the body handles the drug sb773812

Conditions: Schizophrenia

Summary: the purposes of this study are to determine if there is a difference in how sb-773812 is distributed through the bloodstream before and after multiple doses of ketoconazole have been given and to determine if there is a difference in how safe and well tolerated sb-773812 is when given on its own and given with ketoconazole.


Eligibility criteria:
inclusion criteria: * healthy * body weight \>/=50kg and bmi 18.5-29.9 kg/m2 inclusive * normal 12-lead ecg, physical examination and lab screen exclusion criteria: * a history of psychiatric illness, * a history or presence gastro-intestinal, * a hepatic or renal disease or orthostatic hypotension.

Keywords: safety pharmacokinetics,
medical therapy versus sinus surgery for chronic rhinosinusitis: a prospective, multi-institutional study

Conditions: Chronic Rhinosinusitis; Sinusitis

Summary: this investigation is a prospective, multi-institutional cohort study comparing the differences in health-related quality-of-life (hrqol) improvements between subjects electing continued medical management for chronic rhinosinusitis and those electing medical management plus surgical intervention. our hypothesis is 3 fold: 1. that patients electing continued medical management will have less disease severity as measured by ct and baseline hrqol scores, 2. patients undergoing medical management plus ess for chronic rhinosinusitis will experience a larger improvement in health related quality of life (hrqol)compared to patients electing medical management alone, and 3. patients undergoing medical management plus ess for chronic rhinosinusitis will use fewer antibiotics, systemic steroids, and miss fewer days of work/school compared to patients electing medical management alone.

chronic rhinosinusitis (crs) is a common health condition in the united states resulting in more than 500,000 surgical procedures annually. since crs is a disease process that is known to adversely affect quality of life, it is important to understand the short-term and long-term implications of different treatment options as documented by our patients' perception of their quality of life.

Eligibility criteria:
inclusion criteria: * adults (\>= 18 years old) * diagnosed with chronic rhinosinusitis * failed medical management to date * self-selected either sinus surgery or continued medical therapy as next treatment option * able to complete surveys in english exclusion criteria: * unable to complete surveys in english * children (\< 18 years old)
comparative study of long-acting and short acting triptorelin in pcos patients who underwent ivf/icsi

Conditions: In Vitro Fertilization; Polycystic Ovary Syndrome

Summary: to test whether long-acting triptorelin on pituitary down-regulation can improve the clinical pregnancy rate and reduces the incidence of ovarian hyperstimulation syndrome (ohss) in infertile high-risk patients with polycystic ovaries (pcos) who underwent in vitro fertilization (ivf) or intracytoplasmic sperm injection

all patients received standard ovarian stimulation with rfsh under pituitary suppression with gnrh agonist according to a protocol used routinely. the long-acting triptorelin group use long-acting triptorelin 1.875mg during the luteal phase on pituitary down-regulation , the short acting triptorelin use short-acting triptorelin 0.1mg/d,x10d, then 0.05mg/d until e2\ 10mm diameter. ovarian stimulation was started wih 150-250 iu/day of recombinant fsh (gonal f, serono, switzerland); the initial dose was determined by clinical judgement of the clinician according to the patients's age, body mass index, basal fsh and e2. transvaginal ultrasound and e2 measurement were used to monitor follicular growth, and gonadotropin dosages were adjusted accordingly. ovulation was triggered by intramuscular administration of 5000-10,000 iu of human chorionic gonadotropin (hcg, ferring pharmaceuticals) when at least two follicles reached a diameter of 18 mm. serum hcg value were measured at 12 h after hcg trigger using the immunoassay. oocytes were retrieved 36 h after the injection of hcg.

Eligibility criteria:
inclusion criteria: * pcos patients diagnosis by rotterdam consensus on diagnostic criteria who underwent ivf/icsi treatment exclusion criteria: * patients with poor ovarian reserve, * immunological disease, * endometriosis, * uterine abnormality, * endometrium thickness \< 8mm before embryo transfer, * fewer than two good-quality embryos available for transfer or patients with inadequate data for analysis were excluded.

Keywords: pcos long acting triptorelin short acting triptorelin in vitro fertilization
integrating community health workers to improve diabetes prevention

Conditions: Diabetes Mellitus

Summary: cluster randomized trial to test the impact of peer health coaches on prediabetic patients. this study will test a scalable model of peer health coaching to address the millions of patients at risk for diabetes mellitus, using low cost, culturally congruent personnel to promote prevention of diabetes mellitus in patient-centered medical home (pcmh) practice.

this population based trial aims to understand the impact of peer health interventions on panels of patients in a real clinic environment investigators will conduct a cluster-randomized trial to test the impact of peer health coaches on prediabetic patients cared for by patient-centered medical home model (pcmh) teams to: 1. reduce the incidence of type 2 dm in pre-diabetic, pcmh patients; 2. promote weight loss among pre-diabetic patients; 3. increase patient activation levels, a measureable construct of engagement, efficacy, skills, and confidence in managing one's health, among pre-dm patients, resulting in: 1. improved secondary clinical outcomes: better glycemic and blood pressure control, and lower framingham risk scores; 2. increased utilization of preventive services (e.g. move!, telemove!, healthy lifestyles, etc); 3. improved health behaviors (e.g. making dietary and exercise changes); and 4. develop, implement and assess strategies to recruit, train, and integrate peer chw health coaches within the pcmh model. this study will test a scalable model of peer health coaching to address the millions of patients at risk for diabetes mellitus (dm),using low cost, culturally congruent personnel to promote prevention of dm in pcmh practice.

Eligibility criteria:
inclusion criteria: * having at least one hba1c result in the prediabetic range (5.7-6.5%) in the 5 years prior to the start date of phase 2. exclusion criteria: * a diagnosis of dm, based on icd-9 codes applied during ambulatory encounters in the 2 years prior to phase 2 * treatment with dm medication other than metformin (e.g. insulin or oral agents) * age greater than 75 years * exclusion by patient's pcp due to contraindication for lifestyle intervention or chw outreach. * does not speak english or spanish (necessary to communicate with community health worker)
compatibility of a mild, moisturizing hand cleanser for patients with mild to moderate hand dermatitis

Conditions: Hand Dermatosis

Summary: the purpose of this study is to find out if the use of a hand cleanser that adds moisture to the skin will help improve skin rashes caused by frequent hand washing (hand dermatitis).

the objective of this protocol is to evaluate compatibility and potential benefits of daily use of a marketed mild, moisturizing hand cleanser for subjects/patients who experience mild to moderate hand dermatitis induced by frequent cleansing.

Eligibility criteria:
inclusion criteria: * between 18 and 65 years of age * in general good health * hands free of cuts and abrasions * agree to adhere to the requirements listed in the informed consent * willing and able to use a mild, moisturizing, non-antibacterial cleanser for all hand washing purposes for the duration of the test period * willing to refrain from participating in any other clinical research trial for the duration of the study exclusion criteria: * documented allergies to study product components, soaps, latex, or fragrances * history of the following conditions which may affect the response of the skin or the interpretation of the results: insulin dependent diabetes, or peripheral vascular diseases * participating in a concurrent clinical study involving treatment of your hands * currently using a prescription medication for hand dermatitis

Keywords: hand dermatitis